Back to Journals » Biologics: Targets and Therapy » Volume 10

Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimiliars

Authors Perrone V, Saragoni S, Buda S, Broccoli A, Degli Esposti L

Received 8 June 2016

Accepted for publication 19 September 2016

Published 1 December 2016 Volume 2016:10 Pages 157—165

DOI https://doi.org/10.2147/BTT.S114625

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Doris Benbrook

Valentina Perrone,1 Stefania Saragoni,1 Stefano Buda,1 Alessandro Broccoli,2 Luca Degli Esposti1

1CliCon S.r.l., Health, Economics & Outcomes Research, Ravenna, 2Institute of Hematology “L. e A. Seràgnoli”, University of Bologna, Bologna, Italy

Aim: The purpose of this study was to assess the prescription of epoetins and consumption of health care resources (in terms of drug treatments) in naïve patients with hematological malignancies in a real-world setting; in particular, we compared the results between reference product and biosimilar products.
Methods: An observational retrospective study based on administrative and laboratory databases of three local health units was conducted. All adults diagnosed with hematological malignancies and who had received at least one epoetin (either reference product or biosimilars) prescription for the first time between 1 January 2010 and 30 April 2012 (enrollment period) were included. The date of the first prescription of epoetin within the enrollment period was defined as index date (ID). Patients were followed up for 4 weeks after ID (follow-up period) and were investigated for the 1-year period before the ID. The difference between the last hemoglobin (Hb) measurement after ID and the one prior to ID (ΔHb) was evaluated. The drug cost analysis was conducted from the perspective of the Italian National Health System.
Results: Overall, 69 patients were included in the study; 48 of them received reference epoetin product and 21 received biosimilars as first prescription. Among reference product users, the mean ± standard deviation (SD) age was 62.5±14.7 years; this cohort of patients was slightly significantly younger than the biosimilar users (71.8±11.8 years). The mean ± SD overall Hb level prior to treatment was lower among patients who started with biosimilar products (9.6±1.1 g/dL) compared to those who started with a reference product (10.1±2.1 g/dL). No significant differences in ΔHb were observed between biosimilar and originator groups during the follow-up period. The mean ± SD cost per patient was €667.98±573.93 and €340.85±235.73 for the reference product and biosimilar users, respectively (p=0.065).
Conclusion: Our study showed that the use of biosimilar products might contribute to controlling health care costs (in terms of drug treatments) for patients with hematological malignancies being maintained by high-quality anemia therapy. Our findings also showed some discordances regarding the most appropriate therapeutic approach in daily clinical practice.

Keywords: erythropoiesis-stimulating agents, chemotherapy-induced anemia, biosimilar, real-world setting

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Epidemiology, patient profile, and health care resource use for hepatitis C in Italy

Sangiorgi D, Perrone V, Buda S, Boglione L, Cariti G, Lefevre C, Nappi C, Degli Esposti L

ClinicoEconomics and Outcomes Research 2017, 9:609-616

Published Date: 10 October 2017

Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study

Ermini G, Perrone V, Veronesi C, Degli Esposti L, Di Pasquale G

Vascular Health and Risk Management 2017, 13:239-246

Published Date: 5 July 2017

Healthcare resource consumption and cost of care among patients with polycystic kidney disease in Italy

Degli Esposti L, Veronesi C, Perrone V, Buda S, Santoro A

ClinicoEconomics and Outcomes Research 2017, 9:233-239

Published Date: 27 April 2017

Residual cardiovascular risk in patients who received lipid-lowering treatment in a real-life setting: retrospective study

Perrone V, Sangiorgi D, Buda S, Degli Esposti L

ClinicoEconomics and Outcomes Research 2016, 8:649-655

Published Date: 25 October 2016

Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting

Perrone V, Sangiorgi D, Buda S, Degli Esposti L

ClinicoEconomics and Outcomes Research 2016, 8:591-597

Published Date: 14 October 2016

Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis

Sangiorgi D, Benucci M, Nappi C, Perrone V, Buda S, Degli Esposti L

Biologics: Targets and Therapy 2015, 9:119-127

Published Date: 6 November 2015

Adherence to statin treatment following a myocardial infarction: an Italian population-based survey

Monaldi B, Bologna G, Costa GG, D'Agostino C, Ferrante F, Filice M, Grion A, Mingarelli A, Paloscia L, Tettamanti R, Veronesi C, Degli Esposti L

ClinicoEconomics and Outcomes Research 2015, 7:273-280

Published Date: 1 June 2015

Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study

Degli Esposti L, Sangiorgi D, Perrone V, Radice S, Clementi E, Perone F, Buda S

ClinicoEconomics and Outcomes Research 2014, 6:401-407

Published Date: 18 September 2014

Drug adherence to olmesartan/amlodipine fixed combination in an Italian clinical practice setting

Degli Esposti L, Saragoni S, Buda S, Degli Esposti E

ClinicoEconomics and Outcomes Research 2014, 6:209-216

Published Date: 22 April 2014

Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases

Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E

ClinicoEconomics and Outcomes Research 2013, 5:193-201

Published Date: 14 May 2013

Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients

Luca Degli Esposti, Stefania Saragoni, Silvia Benemei, et al

ClinicoEconomics and Outcomes Research 2011, 3:47-54

Published Date: 7 March 2011

Antihypertensive therapy among newly treated patients: An analysis of adherence and cost of treatment over years

Luca Degli Esposti, Stefania Saragoni, Paolo Batacchi, et al

ClinicoEconomics and Outcomes Research 2010, 2:113-120

Published Date: 28 July 2010